Cardiac PET Intensive Virtual Workshop (May 3-4, 2025)-Overview of F-18 Flurpiridaz PET MPI

Video Transcription

Video Summary

Dr. Jamshid Nadahi presents an overview of the recently FDA-approved F18 fluoroperidazepate, a myocardial perfusion imaging tracer. This agent offers significant advantages for cardiac diagnostics, including longer half-life, which allows PET imaging with treadmill tests—addressing limitations posed by rubidium's short half-life. Fluoroperidazepate boasts improved imaging quality, superior diagnostic sensitivity, particularly in certain patient demographics like women, diabetics, and those with higher BMIs, and effectively detects coronary artery disease.<br /><br />Clinical trials (including phases 1-3) confirmed its safety and efficacy, showing lower radiation exposure compared to SPECT imaging, and demonstrated better image resolution and defect detection. PET's segmental myocardial blood flow analysis surpasses traditional methods, enhancing diagnostic performance.<br /><br />Current challenges include the high cost of PET equipment, the need for physician training, and overcoming private insurance reimbursement hurdles. However, the technology’s potential to transition existing PET scanners from more general uses to include cardiac imaging could mitigate some financial concerns. Overall, F18 fluoroperidazepate offers substantial clinical promise, potentially reshaping non-invasive coronary artery disease evaluation.

Keywords

F18 fluoroperidazepate

myocardial perfusion imaging

cardiac diagnostics

PET imaging

coronary artery disease

clinical trials

radiation exposure

diagnostic sensitivity